Drug Resistant Epilepsy Clinical Trial
Official title:
Comparison of Efficacy of Low Glycemic Index Therapy and Modified Atkins Diet Among Children With Drug Resistant Epilepsy: A Randomized Non-inferiority Trial
To compare the efficacy of two less restrictive dietary therapies - LGIT and MAD, used for treatment of drug resistant epilepsy in children
Status | Recruiting |
Enrollment | 110 |
Est. completion date | December 2019 |
Est. primary completion date | December 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 15 Years |
Eligibility |
Inclusion Criteria: - Children aged 1-15 years with drug resistant epilepsy - Willing to come for regular follow-up according to study protocol Drug resistant epilepsy defined as - Seizure frequency >4 seizures per month, while on optimal doses of at least 2 prescribed antiepileptic drugs - For West syndrome, drug resistant epilepsy will be defined as more than 4 clusters of spasms per month despite treatment with antiepileptic drugs and either ACTH(Adrenocorticotrophic hormone) or Vigabatrin Exclusion Criteria: - Surgically remediable causes for DRE - Inborn errors of metabolism - Previously received KD, MAD or LGIT - Known case of 1. Chronic kidney disease 2. Chronic liver disease/GI illness 3. Congenital/acquired heart disease 4. Chronic respiratory illness |
Country | Name | City | State |
---|---|---|---|
India | AIIMS | New Delhi | Delhi |
India | All India Institute of Medical Sciences | New Delhi | Delhi |
Lead Sponsor | Collaborator |
---|---|
All India Institute of Medical Sciences, New Delhi |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of seizure reduction from baseline at 24 weeks of therapy | Mean weekly seizure reduction at 24 weeks divided by Mean weekly seizure measured at baseline multiplied by 100 | At the end of 24 weeks of dietary therapy | |
Secondary | Proportion of children who achieve >50% seizure reduction | Number of children with >50% reduction divided by number of children in each arm | At the end of 24 weeks of dietary therapy | |
Secondary | Incidence of adverse events | Routine hemogram, Renal function test (RFT), Liver function test (LFT) and lipid profile will be assessed for any alterations. Adverse events, vomiting, constipation and diarrhea will be checked by parents record | At the end of 24 weeks of dietary therapy | |
Secondary | Compliance of participants with dietary therapy in each arm will be determined each week, whether satisfactory or unsatisfactory | Weekly compliance assessment of each participant will be done | At the end of 24 weeks of dietary therapy | |
Secondary | Change in Social quotient(SQ) with each dietary therapies | Proportion of children with improvement in Social quotient (SQ) assessed by Vineland Social Maturity Scale (VSMS) at 24 weeks. VSMS consists of 8 subsets - Communication skills, General self-help ability, Locomotion skills, Occupation skills, Self-direction, Self-help eating, Self-help dressing, Socialization skills. Social age is calculated by adding the scores of all subsets. Social quotient (SQ) is calculated by social age divided by chronological age multiplied by 100. | At the end of 24 weeks of dietary therapy | |
Secondary | Change in Quality of Life of participants who are less than 4 years of age at 24 weeks as compared to baseline | In children less than 4 years quality of life is assessed by PedsQL (Pediatric Quality of life inventory). PedsQL consists of 21 questions each having 5 responses with scores 0,1,2,3 and 4. Minimum score is 0 and maximum is 84. Quality of life is poor with larger score. | At the end of 24 weeks of dietary therapy | |
Secondary | Change in Quality of Life of participants who are more than or equal to 4 years of age at 24 weeks as compared to baseline | In children with age 4 years or more, QOLCE 55 (Quality of life in childhood epilepsy questionnaire) is used to assess quality of life. QOLCE 55 consists of 55 questions which are classified into 4 categories. Each question have 5 responses with scores as 0,25,50,75 and 100. Mean score of each category is calculated and final score calculated by mean of the scores of 4 categories. Minimum score is 0 and maximum is 100. Quality of life is better with larger score. | At the end of 24 weeks of dietary therapy | |
Secondary | Change in Quality of Life of caregivers at 24 weeks as compared to baseline | Quality of life of caregivers is assessed by WHOQOL-BREF. WHOQOL BREF contains 26 items categorized into 4 domains. For each question response is scored 1,2,3,4 or 5. Total raw score is then calculated and is converted to transformed score. Minimum score is 0 and maximum is 100. Quality of life is poor with smaller score. | At the end of 24 weeks of dietary therapy | |
Secondary | Gut microbiota (GM) analysis pre and post dietary therapy | Changes in percentage distribution of various micro organisms in gut microbiota after dietary therapy as compared to baseline GM | At the end of 24 weeks of dietary therapy | |
Secondary | Change in behavioral abnormalities with each dietary therapy | Behavior assessment is done using Child behavior check list (CBCL).This questionnaire contains 100 and 113 questions for age groups of 1 ½ - 5 years and 6-18 years respectively. Score of 2 will be given for a response of 'very true', 1 for a response of 'somewhat true' and 0 for 'not true'. Total score is obtained by adding all the subsets. Subsets for age 1.5 years to 5 years include - Emotionally reactive, anxious/depressed, somatic complaints, withdrawn, sleep problems, attention problems, aggressive behavior and other problems. Subsets for age 6 years to 12 years include - Anxious/Depressed, withdrawn, somatic complaints, social problems, thought problems, attention problems, rule breaking behavior, aggressive behavior, other problems. Raw score is then converted to T score according to the published charts. Minimum T score is 28 and maximum is 100. Larger score indicates more behavioral problems. | At the end of 24 weeks of dietary therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04378075 -
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
|
Phase 2/Phase 3 | |
Recruiting |
NCT05928598 -
Goals for Epilepsy Clinic Visits Trial
|
N/A | |
Recruiting |
NCT05539287 -
Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy
|
Phase 2 | |
Not yet recruiting |
NCT04601974 -
Lentiviral Gene Therapy for Epilepsy
|
Phase 1/Phase 2 | |
Completed |
NCT02982824 -
Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy
|
N/A | |
Recruiting |
NCT05485558 -
the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy
|
Phase 2 | |
Not yet recruiting |
NCT04553354 -
Cortical Resections in Drug Resistant Epilepsy
|
||
Recruiting |
NCT04999046 -
NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
|
N/A | |
Recruiting |
NCT04714996 -
Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
|
Phase 2 | |
Recruiting |
NCT04839601 -
RNS System RESPONSE Study
|
N/A | |
Recruiting |
NCT06059157 -
Epileptogenic Network Visualisation With Advanced MRI
|
N/A | |
Recruiting |
NCT05947656 -
Evaluation of the NaviFUS System in Drug Resistant Epilepsy
|
N/A | |
Recruiting |
NCT05393518 -
Electroclinical Correlation of Anxiety
|
N/A | |
Not yet recruiting |
NCT05555537 -
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy
|
||
Completed |
NCT03419000 -
Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY
|
N/A | |
Enrolling by invitation |
NCT06341075 -
Real-World Study of Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Drug-resistant Epilepsy
|
N/A | |
Not yet recruiting |
NCT05527093 -
Cartography of Social Cognition Network and Their Alterations in Patients With Epilepsy
|
N/A | |
Recruiting |
NCT05697614 -
The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children
|
Phase 4 | |
Recruiting |
NCT06309251 -
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
|
||
Recruiting |
NCT06432907 -
StereoEEG Motor Neuronal Potentials Decoding
|
N/A |